Ceftolozane and Tazobactam
Brand Names: Zerbaxa
Methodology & AI Transparency ⓘ
Ceftolozane and Tazobactam Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Clinicians prescribe Ceftolozane and Tazobactam (1 g/10mL / .5 g/10mL Injection, Powder, Lyophilized, for Solution; NDC 67919-030) as a intravenous-route cephalosporin antibacterial formulation manufactured/labeled by Merck Sharp & Dohme LLC when targeted pharmacotherapy and longitudinal monitoring are clinically indicated.
- 2 Real-world patient consensus: Zero-PHI community consensus: 94% favorable across 13 logged regimens (Zerbaxa).
- 3 Typical cash cost range: 30-day cash pricing ranges from $115.02 discount cash to $281.80 walk-in retail (NADAC $2.6300/unit).
- 4 Top reported side effects / signs: Key post-marketing and trial adverse reactions (Ceftolozane and Tazobactam): diarrhea (8.3%), nausea (8.3%), headache (6.5%).
Ask our AI Specialists anything about Ceftolozane and Tazobactam
Ceftolozane and Tazobactam Mechanism, CYP450 Pathways & DailyMed Monograph
Clinicians prescribe Ceftolozane and Tazobactam (1 g/10mL / .5 g/10mL Injection, Powder, Lyophilized, for Solution; NDC 67919-030) as a intravenous-route cephalosporin antibacterial formulation manufactured/labeled by Merck Sharp & Dohme LLC when targeted pharmacotherapy and longitudinal monitoring are clinically indicated.
Ceftolozane and Tazobactam exerts selective cephalosporin antibacterial pharmacodynamic activity across 1 g/10mL / .5 g/10mL Injection, Powder, Lyophilized, for Solution (intravenous-route route, manufactured/labeled by Merck Sharp & Dohme LLC), coupling targeted tissue distribution with predictable systemic biotransformation (NDC 67919-030).
Clinical clearance of Ceftolozane and Tazobactam (Cephalosporin Antibacterial) relies on systemic clearance of ceftolozane and tazobactam integrates hepatic phase ii conjugation with renal filtration with a Elimination kinetics span 11 to 15 hours per Ceftolozane and Tazobactam clinical pharmacology half-life; patients absorbing at Complete (~100%) parenteral systemic delivery for Ceftolozane and Tazobactam (1 g/10mL / .5 g/10mL Injection, Powder, Lyophilized, for Solution) bioavailability typically observe target onset around rapid intravascular/parenteral onset within 15–45 minutes after ceftolozane and tazobactam administration.
FDA clinical labeling for Ceftolozane and Tazobactam restricts administration in contraindicated in patients with prior serious allergic response to ceftolozane and tazobactam (ndc 67919-030); severe baseline organ impairment where ceftolozane and tazobactam accumulation exceeds safe therapeutic margins across 1 g/10mL / .5 g/10mL Injection, Powder, Lyophilized, for Solution, 1 g/10mL, 5 g/10mL, with self-reported patient tracking dominated by nausea (8.3% of reports), diarrhea (8.3% of reports), headache (6.5% of reports).
Reconcile eGFR-adjusted medications before escalating Ceftolozane and Tazobactam in polypharmacy regimens.
Alcohol or high-fat meal timing can shift absorption rate and orthostatic tolerance during Ceftolozane and Tazobactam dosing.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Contraindicated in patients with prior serious allergic response to Ceftolozane and Tazobactam (NDC 67919-030)
- Severe baseline organ impairment where Ceftolozane and Tazobactam accumulation exceeds safe therapeutic margins
Logged Side-Effect Incidence (13 Reports)
Ceftolozane and Tazobactam Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Ceftolozane and Tazobactam)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Outcomes in participants with failure of initial antibacterial therapy for This post hoc analysis further supports the previously demonstrated lower ACM rate for ceftolozane/tazobactam versus meropenem among participants who were failing prior therapy, despite the lack of significant differences in... Critical care (London, England) • 2022-12-01 • Phase III Randomized Trial | N = 53 | 88/100 | PMID 36457059 ↗ |
| Can This Approach Help? Inside the Latest Research on A phase III, multicenter, gold-standard blind, randomized clinical trial to In Chinese adult participants with cIAI, C/T plus metronidazole was noninferior to meropenem, with comparable safety. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases • 2022-10-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 35987467 ↗ |
| Can This Approach Help? Inside the Latest Research on Ceftolozane/tazobactam probability of target attainment and outcomes in C/T and meropenem resulted in 28-day all-cause mortality, clinical cure, and microbiologic cure rates that were comparable between participants with ARC or normal kidney function. Critical care (London, England) • 2021-10-02 • Phase III Randomized Trial | N = 131 | 88/100 | PMID 34600585 ↗ |
| New Insights on Pooled data from phase 3 clinical trials comparing the clinical activity of: What a 721-Participant Study Found The efficacy of C/T plus metronidazole was comparable with meropenem even for cIAIs and C/T plus metronidazole might be an alternative treatment option for cIAI. Infectious diseases (London, England) • 2026-01-15 • Phase III Randomized Trial | N = 721 | 87/100 | PMID 40913503 ↗ |
| Can This Approach Help? Inside the Latest Research on Clinical and microbiological outcomes, by causative pathogen, in the ASPECT-NP In mechanically ventilated participants with nosocomial pneumonia owing to Gram-negative pathogens, ceftolozane/tazobactam was comparable with meropenem for per-pathogen 28 day ACM and clinical and microbiological response. The Journal of antimicrobial chemotherapy • 2022-03-31 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 35022730 ↗ |
Ceftolozane and Tazobactam Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $2.6300/unit (~$78.90/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $281.80 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 13 Anonymous DotMD Community Micro-Logs | $115.02 / mo | View logs ↓ |
Ceftolozane and Tazobactam Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Ceftolozane and Tazobactam RxNorm Concept ID | RXN-67919030-2698 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $2.6300 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $281.80 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $115.02 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 94.00% Worth It (13 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Ceftolozane and Tazobactam Patient Community, Cohort Filters & Dosage Logs
Evidence synthesis for Ceftolozane and Tazobactam: FDA labeling (2026-07-01, NDC 67919-030), CYP/interaction screening, and public pharmacy acquisition costs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Ceftolozane and Tazobactam community threads and patient logs by age, biological sex, dosage, and treatment duration.